Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

The FDA granted “Safe to Proceed” for the pivotal Phase 3 sTEADfast clinical study, a positive regulatory step for the program. The company also appointed Craig Gibbs, PhD, MBA as President and CEO and added Ellen Lubman, MBA as Chief Business and Strategy Officer, alongside Tim Clackson, PhD joining the Board of Directors. Overall, the updates suggest incremental progress on clinical execution and leadership alignment, which may support near-term sentiment for the stock.